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Abstract
EphA2 is a receptor tyrosine kinase that has been shown to be overexpressed in a variety of human tumor types.
Previous studies demonstrated that agonist monoclonal antibodies targeting EphA2 induced the internalization
and degradation of the receptor, thereby abolishing its oncogenic effects. In this study, the in vitro and in vivo
antibody-dependent cell-mediated cytotoxicity (ADCC) activity of EphA2 effector–enhanced agonist monoclonal
antibodies was evaluated. With tumor cell lines and healthy human peripheral blood monocytes, the EphA2 anti-
bodies demonstrated ∼80% tumor cell killing. In a dose-dependent manner, natural killer (NK) cells were required
for the in vitro ADCC activity and became activated as demonstrated by the induction of cell surface expression of
CD107a. To assess the role of NK cells on antitumor efficacy in vivo, the EphA2 antibodies were evaluated in xeno-
graft models in severe compromised immunodeficient (SCID) mice (which have functional NK cells and mono-
cytes) and SCID nonobese diabetic (NOD) mice (which largely lack functional NK cells and monocytes). Dosing
of EphA2 antibody in the SCID murine tumor model resulted in a 6.2-fold reduction in tumor volume, whereas
the SCID/nonobese diabetic model showed a 1.6-fold reduction over the isotype controls. Together, these results
demonstrate that the anti–EphA2 monoclonal antibodies may function through at least two mechanisms of action:
EphA2 receptor activation and ADCC-mediated activity. These novel EphA2 monoclonal antibodies provide addi-
tional means by which host effector mechanisms can be activated for selective destruction of EphA2-expressing
tumor cells.
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Introduction
EphA2 is a member of the Eph family of receptor tyrosine kinases
(RTKs), the largest family of RTKs consisting of at least 15 family
members [1,2]. During development, the Eph receptors and ligands
are involved in cell-cell interactions and cell migration in morphoge-
netic processes. In cancer, EphA2 is overexpressed in multiple tumor
types including breast, prostate, lung, cervical, colon, esophageal, gastric,
ovarian, bladder, renal cell carcinomas, melanoma, and gliomas [2–9].
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In ovarian, cervical, and esophageal cancers, high levels of EphA2 expres-
sion have been correlated with poor patient survival rates [10–15]. In
addition, EphA2 is expressed on tumor endothelial cells in the tumor
neovasculature of primary tumor samples, thus presenting another ave-
nue for targeting tumor growth by the inhibition of angiogenesis [1,2].
Several preclinical studies have demonstrated that EphA2 plays a role
in cancer. When the nontransformed MCF10A cell line is engineered
to express EphA2, the cell line becomes transformed and grows in soft
agar and forms tumors in vivo [16]. Furthermore, the down-regulation
of EphA2 with small interfering RNA results in an increase of apop-
tosis in vitro and in vivo and in the suppression of in vivo xenografts
[17,18]. Another study used adenoviral-expressed EphrinA1 to down-
regulate EphA2 protein in MDA-MB-231 breast tumor cells, and this
also decreased their growth in soft agar and in xenograft models [19].
In addition, others have reported similar results whereby EphA2 anti-
body treatment of tumor cell lines decreased EphA2 protein levels,
which resulted in decreased tumor cell growth in soft agar and suppres-
sion of tumor growth in xenograft models [20–22].
The development of monoclonal antibody therapeutics for oncology
has grown tremendously in the past decade. Currently, there are six
monoclonal antibodies and three immunoconjugates approved in the
United States for oncology and many more in development [23,24].
The function of the antibodies can vary from Avastin, which binds
to vascular endothelial growth factor and blocks its ability to bind
to its receptor, to Rituxan, which binds to CD20 present on malignant
B cells and functions, in part, through an antibody-dependent cell-
mediated cytotoxicity (ADCC)–dependent mechanism [24]. For most
of these monoclonal antibodies, several mechanisms of action have
been proposed, including receptor down-regulation, induction of
apoptosis, ADCC, and complement-dependent cytotoxicity [24,25].
Frequently, the emerging mechanism of action is ADCC. For instance,
clinical studies with Rituxan demonstrated that ADCC plays a role in
its therapeutic activity and that polymorphisms in the Fc receptor can
determine the degree of efficacy achieved [26,27]. Recently, a similar
finding was observed for Herceptin where the presence of the FcγRIII
158V/V genotype correlated with response rates and progression-free
survival in breast cancer patients [28].
Because ADCC activity may be a significant component of the
efficacy of monoclonal antibodies for cancer therapy, we investigated
the in vitro and in vivo ADCC activity of an EphA2 agonist antibody
that has been modified to enhance ADCC effector activity. The re-
sults show that modifications to the Fc portion of the EphA2 anti-
body enhance binding to FcγRIIIa thereby increasing in vitro ADCC
activity and efficacy in xenograft models. Our data strongly suggest
that natural killer (NK) cells become activated and are required for
ADCC activity and that mutations in the Fc region of an EphA2-
targeting antibody enhanced binding to FcγRIIIa and, to a large extent,
overrode the effects of FcγRIIIa polymorphism status on effector-
mediated cytotoxic activity.
Materials and Methods
Cell Lines and Culture
The human cell lines A549 (non–small cell lung cancer cell
(NSCLC)), MDA-MB-231 (breast adenocarcinoma), SKOV3 (ovarian
adenocarcinoma), and SKMel28 (malignant melanoma) were obtained
from American Type Culture Collection (ATCC, Manassas, VA) and
cultured in the recommended media. The M21 cell line was a kind gift
from David Cheresh, PhD, Scripps Research Institute, La Jolla, CA.
Antibodies
EphA2 antibodies, B233 and 3F2, were generated as previously
described [21,29]. 3F2-3M was generated from the Fc triple substi-
tution of 3F2 and cloned into NS0 cells as an IgG1 isotype. In brief,
three amino acid substitutions, namely, S239D, A330L, and I332E,
were introduced into the Fc region of 3F2 by QuickChange II XL
site–directed mutagenesis kit (Stratagene, San Diego, CA). The Fc
mutant was generated by two sequential site-directed mutagenesis
using oligo S239DF, S239DR, A330L/I332EF, and A330L/I332ER
as primers and 3F2 as template. The mutations were confirmed by
DNA sequencing.
Mouse IgG1 anti–human APC-conjugated CD3, APC-Cy7–
conjugated CD19, PerCP-conjugated CD14, PE-Cy5–conjugated
CD107a, and PE-conjugated CD4, CD8, and CD56 were purchased
from BD Pharmingen (San Jose, CA). Mouse IgG1 anti–human APC–
conjugated CD16, Pacific Blue–conjugated CD8, and PE-Cy7–
conjugated CD45 were purchased from Biolegend (San Diego, CA).
Mouse IgG2 anti–human PE-Cy5.5–conjugated CD3 was purchased
from Caltag Laboratories (Burlingame, CA). In addition, EphA2 and
isotype control antibodies were conjugated to AlexaFluor488 accord-
ing to Molecular Probes’ AlexaFluor488 Monoclonal Antibody Label-
ing Kit protocol (Invitrogen, Carlsbad, CA).
EphA2 Antibody Binding Constant—Surface Plasmon
Resonance (Biacore)
The interaction of the EphA2 antibody 3F2-3M with immobilized
EphA2-Fc was monitored by surface plasmon resonance detection using
a Biacore 3000 instrument (Biacore, Pittsburgh, PA). Data were fitted
to a 1:1 Langmuir binding model. This algorithm calculates both the
kon and the koff, from which the apparent equilibrium dissociation
constant, KD, is deduced as the ratio of the two rate constants (koff/
kon). Selectivity to EphA2 over other Eph family members was fur-
ther characterized by ELISA using commercially available Eph fusion
proteins, and 3F2-3M demonstrated high affinity and specificity for
human EphA2.
Binding of EphA2 Antibodies to Fcγ Receptors—Surface
Plasmon Resonance (Biacore)
The interaction of soluble human FcγRIIIA (F158 allotype)
and murine FcγRIV with immobilized EphA2 antibodies, 3F2 and
3F2-3M, was monitored by surface plasmon resonance detection
using a Biacore 3000 instrument. The different humanized IgG1s
were coupled to the dextran matrix of a CM5 sensor chip at a sur-
face density of between 7711 and 9608 RU. Human FcγRIIIA
and murine FcγRIV were used in equilibrium binding experiments
at concentrations ranging from 16 μM to 0.98 nM at a flow rate
of 5 μl/min. Dilutions and binding experiments were carried out in
50 mM Hank's buffered saline buffer containing 0.01 M HEPES,
pH 7.4, 0.15 M NaCl, 3 mM EDTA, and 0.005% P-20. Data were
typically collected for 50 minutes, and a 30-second pulse of 5 mM
HCl was used to regenerate the surfaces. Human FcγRIIIA and
murine FcγRIV were allowed to flow over an uncoated cell, and the
sensorgrams from these blank runs were subtracted from those ob-
tained with IgG-coupled cells. Values for KD were determined from
the corresponding binding isotherms.
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In Vitro EphA2 Activation Assays
The EphA2 activation assays were performed as previously described
[21]. Human cancer cells, 3 × 105 per well, were seeded into six-well
plates containingmediumwith 10% fetal bovine serum. After a 24-hour
incubation, cells were treated for 15 minutes at 37°C with serum-
containing medium including titrated doses (0.1-50 μg/ml) of EphA2
antibody, 10 μg/ml positive control antibody, 10 μg/ml isotype control
antibody, or no treatment. After incubation, wells were washed with
cold phosphate-buffered saline (PBS) and cells were lysed with 1%
triton lysis buffer (TX100; Boston Bioproducts, Boston, MA) contain-
ing protease inhibitors. Approximately 100 to 300 μg of protein for
each sample was immunoprecipitated with the EphA2 monoclonal
antibody, D7 (Upstate, Charlottesville, VA) and rabbit anti–mouse pro-
tein A sepharose beads (Chemicon, Temecula, CA; Sigma-Aldrich, St.
Louis, MO) for 90 minutes at 4°C. Beads were washed three times
with TX100 and stored in 6× gel loading buffer (Boston Bioproducts)
at −20°C until analysis by SDS-PAGE and immunoblot analysis. Phos-
phorylated EphA2 was detected by probing with the antiphosphotyro-
sine monoclonal antibody, 4G10 (Upstate). Blots were stripped and
reprobed with an EphA2 monoclonal antibody (Invitrogen) to deter-
mine total EphA2 levels.
Lactate Dehydrogenase Release ADCC Assays
Endogenous EphA2-expressing tumor cell lines were harvested using
0.05% trypsin, washed with 1× PBS, and treated with EphA2 anti-
bodies at 500, 50, and 5 ng/ml on ice for 20 minutes. Peripheral blood
monocytes (PBMCs) were isolated from human whole blood obtained
from healthy donors using a Lymphocyte Separation Medium (MP
BioMedicals, Solon, OH) and washed three times with 1× PBS. Isolated
PBMCs were incubated with EphA2-expressing cells that were pre-
treated with EphA2 antibodies at an effector-to-target ratio of 100:1,
50:1 or 25:1 for 4 hours at 37°C. After the 4-hour incubation period,
the cell supernatant was transferred to a 96-well plate to determine the
amount of lactate dehydrogenase (LDH) released using a colorimetric
assay (Promega, Madison, WI). Percent cytotoxicity was calculated as
follows: percent cytotoxicity = (experimental − effector spontaneous −
target spontaneous) / (target maximum − target spontaneous) × 100,
where “experimental” corresponds to the signal measured in a treated
sample, “effector spontaneous” corresponds to the signal measured in
the presence of PBMCs alone, “target spontaneous” corresponds to the
signal measured in the presence of tumor cells alone, and “target maxi-
mum” corresponds to the signal measured in the presence of detergent-
lysed tumor cells.
Additional studies used purified NK cells in the LDH release assays.
Human whole blood was obtained, and PBMCs were isolated as de-
scribed previously. Natural killer cells were isolated according to the
NK cell isolation kit manufacturer’s protocol for negative selection
(Miltenyi Biotec, Auburn, CA). The magnetically labeled non–NK
cells were depleted from the PBMC population by retention on the
column. In contrast, non–NK cells were isolated by negative selection
using a CD56 MicroBead Kit (Miltenyi Biotec). The magnetically
labeled CD56+ cells were depleted from the PBMC population through
retention on the column.
Antibody Binding to Human Blood Cell Subpopulations
Human whole blood was collected from healthy donors in sodium
citrate cell preparation tubes. These were spun at 1700g for 15 minutes
at room temperature. The red blood cells were contained beneath
the density gradient, and the supernatant, containing PBMCs, was
decanted. Peripheral blood monocytes were washed three times in 1×
PBS and resuspended in Dulbecco’s PBS containing 1% BSA (FACS
buffer). Peripheral blood monocytes (1 × 106 cells/well) were treated
with 10 μg/ml AlexaFluor488-labeled EphA2 and control antibodies
then stained with 5 μl of directly conjugated cell surface markers
(including CD3-APC, CD4-PE, CD8-PE, CD19-APC-Cy7, CD14-
PerCP, CD56-PE, and CD16-APC) for 30 minutes at 4°C. Cells were
washed twice in FACS buffer and either analyzed within 1 hour or fixed
in 4% formaldehyde (Tousimis, Rockville, MD) and stored overnight
for flow cytometric analysis on a LSRII (BD Biosciences, San Jose, CA).
To include neutrophils in the antibody binding assays, whole blood
(100 μl/well) was incubated (30 minutes at 4°C) with 10 μg/ml
AlexaFluor488-labeled EphA2 or control antibodies in the presence
of 5 μl/well of each cell surface marker (group 1: CD45-PE-Cy7,
CD14-PerCP, CD16-APC, and CD56-PE; Group 2: CD3-PE-
Cy5.5, CD8-Pacific Blue, CD4-PE, CD16-APC, and CD19-APC-
Cy7). Red blood cells were lysed with 200 μl of ammonium chloride
(Stem Cell Technologies, Vancouver, British Columbia, Canada) for
10 minutes at 37°C and washed twice with FACS buffer before flow
cytometric analysis on a LSRII. FlowJo software (Treestar, Ashland,
OR) was used to analyze all data obtained from flow cytometric analysis.
Table 1. 3F2-3M Biochemical Properties.
A)
kon, × 10
5 (1/Ms) koff, ×10
5 (1/s) K D (pM)
3F2-WT 5.4 (1.32) 3.0 (2.18) 60 (53)
3F2-3M 2.7 (1.36) 4.4 (0.08) 163 (89)
B)
IgG Human FcγRIIIA
(KD, nM)
Human FcγRIIIA
Fold Improvement
Murine FcγRIV
(KD, nM)
Murine FcγRIV
Fold Improvement
158F 158V 158F 158V — —
3F2-WT 2878 (153) 519 (63) N/A N/A 536 (66) N/A
3F2-3M 28 (6) 9 (2) 103 58 5 (0) 107
A) The binding of the EphA2 antibody 3F2-3M to recombinant EphA2-Fc was determined by Biacore assessment as described in Materials and Methods. Data are presented as mean (SD).
B) Similar to A), the dissociation constants of the EphA2 antibodies 3F2-WT and 3F2-3M for human CD16 (FcγRIIIa) and murine FcγRIV were determined by Biacore analysis. In the case of
human FcγRIIIa, the two CD16 allotypes, 158F and 158V, were evaluated to determine whether this polymorphism may impact binding. Data are presented as mean (SD) from two independent sets
of measurements.
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Natural Killer Cell Activation Status—CD107a Assay
Freshly isolated PBMCs (1 × 106 cells/well) were incubated with
A549 or SKMel28 cells (1 × 106 cells/well) at a 1:1 ratio in the presence
of varying concentrations of unlabeled EphA2 or control antibodies.
Peripheral blood monocytes with medium alone served as negative con-
trols and PBMCs stimulated with the leukocyte activation cocktail
with GolgiPlug (BD Biosciences) served as positive controls. Effector
and target cells were coincubated in 100 μg/ml to 0.1 ng/ml antibody
and stained with 5 μl of PE-Cy5–conjugated CD107a (BD Bio-
sciences) for 3 hours at 37°C. Golgi-Stop (BD Biosciences) was added
after the first hour of incubation, according to the manufacturer’s
protocol. Natural killer cell surface markers, 5 μl of PE-conjugated
CD56 (US Biological, Swampscott, MA) and 5 μl of FITC-conjugated
CD3 (BD Biosciences), were added, and cells weer incubated for an
additional 30 minutes at 4°C. Samples were then washed twice in
FACS buffer, and flow cytometric analysis was performed on LSRII.
Assessment of FcγRIIIa (CD16) Polymorphisms
To determine the FcγRIIIa genotype of the healthy human donors,
heparinized whole blood was processed using the Bio-Fast DNAExtrac-
tion Kit according to the manufacturer’s instructions (Bio-Synthesis,
Inc., Lewisville, TX). Purified genomic DNAwas ethanol-precipitated,
and the concentration was determined using the Nanodrop spectropho-
tometer (Nanodrop Technologies, Wilmington, DE). Single nucleotide
polymorphism analysis was performed using the Plexor System (Pro-
mega) where 50 to 100 ng of purified DNA was amplified using the
following primer pair: 5′-CCGGAGAAACATTTTTACTCC-
CAAAAA-3′ for the TTT genotype (F phenotype), 5′-CGTCACGA-
TATTTTTACTCCCAACA-3′ for the GTT genotype (V phenotype),
and the anchor primer 5′-TTCTGACTTCTACATTCCAAAAGC-3′.
Positive reactions for each genotype were measured, and interpolated
homozygous and heterozygous phenotypes were determined.
In Vivo Tumor Xenograft Studies
The MDA-MD-231 human breast adenocarcinoma cell line
was grown in monolayer culture and harvested by trypsinization.
Athymic nu/nu, severe compromised immunodeficient (SCID;
Harlan, Sommerville, NJ) or SCID/nonobese diabetic (NOD) (Harlan;
or Taconic, Germantown, MA) female mice 4 to 6 weeks of age were
injected subcutaneously either into the right flank or into the mam-
mary fat pad with 5 × 106 or 2 × 106 MDA-MB-231 tumor cells,
respectively. Treatments of PBS, isotype control, or anti-EphA2 anti-
bodies were administered intraperitoneally at a dose of 10 mg/kg in
PBS. The first dose was given just before or the day after the cell implan-
tation then continued twice weekly. Taxol, a positive control, was
administered intravenously at 10 mg/kg diluted in 0.9% aqueous saline
solution. Tumor growth was monitored twice weekly by caliper mea-
surements [21]. In addition, only SCID and SCID/NOD mice with
less than 100 ng/ml ofmouse IgG, as assessed by ELISA (Pierce Biotech-
nology, Rockford, IL), were used for the study to ensure the animal’s
compromised immune status.
Statistical Analyses
Two-way analysis of variance using GraphPad PRISM software
(GraphPad Software, Inc., San Diego, CA) was used to assess differ-
ences in NK cell CD107a expression. Statistical differences in ADCC
activity across FcγRIIIa allotypes were determined using a 1-tailed,
paired standard t test (SAS, Cary, NC). For all subcutaneous tumor
comparisons, groups were analyzed using a 2-tailed Student’s t Test
assuming equal variance (homoscedastic) and the Mann-Whitney
method. Statistical calculations were performed using SigmaStat
Version 3.01A 4.0 software (Systat Software, Inc., San Jose, CA).
Results
Characterization of an Agonist Monoclonal Antibody
Targeting EphA2 with an Engineered Fc Region
The antibody 3F2-3Mwas generated from the murine parental anti-
body B233 and humanized antibody 3F2, through three amino acid
substitutions in the Fc portion of the molecule (described in Materials
andMethods) [21,29]. To verify that modifications to the Fc portion of
3F2 did not alter interaction with EphA2, the antibody dissociation/
rate constants were assessed using Biacore (Table 1A). The affinity of
3F2-3M and 3F2-WT to human EphA2 were similar with KD values
of 163 and 60 pM, respectively (Table 1A).
To determine whether the 3M mutations altered the interaction of
soluble human FcγRIIIA (F158 and V158 allotypes) with immobilized
EphA2 antibodies, Biacore binding analysis was performed with
3F2-WTand 3F2-3M. Results demonstrate that dissociation constants
for the interaction of 3F2-3M with FcγRIIIA/F158 and FcγRIIIA/
V158 were estimated at 28 and 9 nM, respectively (Table 1B). This
Figure 1. Characterization of 3F2-3M. (A) The EphA2 agonist activ-
ity of 3F2-3Mwas determined by evaluating EphA2 phosphorylation
in MDA-MB-231 cells at concentrations from 0.1 to 50 μg/ml similar
to that previously described [21]. (B) The binding of 3F2-3M to human
blood cell subpopulations was determined using healthy human
PBMCs and characterizing cell subpopulations as described inMate-
rials andMethods. Bindingwas demonstrated toNK cells andmono-
cytes where a statistically significant 100- to 250-fold increase in
binding to NK cells was observed with 3F2-3M compared to 3F2-WT
(P = .002). Error bars, SD.
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translated into respective affinity improvements of 103- and 58-fold
when compared with the 3F2-WTantibody. In addition, to determine
whether the enhanced binding of 3F2-3M and 3F2-WT extended
across species to murine FcγRIV, the mouse-equivalent receptor to
human FcγRIIIA, additional Biacore studies were performed. As dem-
onstrated in Table 1B, an equivalent ∼100-fold improvement in affinity
was demonstrated for the binding of 3F2-3M to mouse FcγRIV com-
pared with the binding of 3F2-WT to mouse FcγRIV.
To confirm that the agonist properties of the 3F2-3M antibody were
not altered, EphA2 receptor phosphorylation studies were performed
[21]. 3F2-3M treatment resulted in a dose-responsive increase in
EphA2 protein phosphorylation, which saturated at 20 μg/ml in the
MDA-MB-231 breast cancer cell line that express endogenous EphA2
(Figure 1A). These results were similar to data generated with 3F2-WT
and the parental antibody, B233 (Figure W1 and data not shown
[21]). Furthermore, similar results were obtained with additional can-
cer cell lines that expressed endogenous EphA2 protein (data not
shown; Figure W2).
Because the affinity to FcγRIIIA was improved (Table 1B), we ana-
lyzed the binding of 3F2-3M to various T- and B-cell subpopulations in
human PBMCs by FACS analyses. Minimal binding of both 3F2-WT
and 3F2-3M was observed for helper T, cytotoxic T, B, and NK/T cells
(Figure 1B). Binding to monocytes was observed with both 3F2-3M
and 3F2-WT. With 3F2-WT, binding could be abolished in the pres-
ence of Fc-blocking reagent, which suggests that the binding was
mediated through the interaction of the Fc region and not due to
the EphA2 expression on this cell population (data not shown).
More importantly, 3F2-3M demonstrated an approximately 100-fold
increase in binding to NK cells when compared with 3F2-WT
(Figure 1B; P = .0002). Given the expression of FcγRIIIA on NK cells
and the increased affinity of 3F2-3M for FcγRIIIA shown in Table 1B,
the interaction is believed to also occur through the Fc portion of the
molecule. Additional studies evaluating cell subpopulations in whole
blood revealed 3F2-3M, but not 3F2-WT, bound to neutrophils at
comparable levels to NK cells (data not shown).
Potent ADCC Activity by 3F2-3M
The ADCC activity of 3F2-3M was assessed using a panel of
human solid tumor cell lines that express endogenous EphA2 as target
cells and healthy donor human PBMCs as effector cells in an in vitro
assay based on LDH release on cell lysis. As shown in Figure 2, 3F2-
3M induced significant cytotoxicity in the SKOV3 (Figure 2A), A549
(Figure 2B), and MDA-MB-231 (Figure 2C) cell lines. At concentra-
tions from 5 to 500 ng/ml and effector-to-target ratios from 25:1 to
100:1, 3F2-3M elicited 10% to 80% cytotoxicity in a dose-dependent
manner when compared with the isotype control (Figure 2). Although
Figure 2. EphA2 antibodies elicit ADCC activity in vitro. The ADCC activity of 3F2-3Mwas assessed using healthy donor PBMCs as effectors
and SKOV3 ovarian cancer (A), A549 NSCLC (B) and MDA-MB-231 breast cancer (C) cell lines as targets as described in Materials and
Methods. Cytotoxicity was observed in a dose-dependent and effector-to-target ratio manner. Concentrations of 3F2-3M or isotype control
antibodies used were 5 ng/ml (diamonds), 50 ng/ml (hatched lines), or 500 ng/ml (solid bars). Little to no cytotoxicity was observed when
3F2-3M was evaluated in the SKMel28, a non–EphA2-expressing melanoma cell line (D). Error bars, SEM. Data are representative of three
independent experiments.
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the ADCC activity did not directly correlate to EphA2 expression
levels, it may be related to the inherent sensitivity of the cancer cells to
ADCC-mediated killing and to the overall amounts of LDH within
each cell type (Table W1). In addition, minimal cytotoxicity (0%-
4%) was observed using an EphA2-negative cancer cell line, SKMel28
(Figure 2D), suggesting the specificity of 3F2-3M for EphA2-expressing
target cells.
Next, we assessed if NK cells played a predominant role in the
ADCC activity of 3F2-3M. EphA2-expressing cell lines, pretreated
with 3F2-3M, were incubated with purified NK and PBMCs lacking
NK cells from healthy donors in vitro. Results demonstrated that
3F2-3M elicited a potent and reproducible ADCC activity in the
presence of human purified NK cells but not NK-depleted PBMCs
(Figure 3). In the presence of NK cells, 3F2-3M was able to elicit
17% to 33% cytotoxicity in a breast carcinoma cell line, MDA-
MB-231 (Figure 3A), and 79% to 93% cytotoxicity in a NSCLC cell
line, A549 (Figure 3B), at concentrations ranging from 5 to 500 ng/
ml and an effector-totarget ratio of 10:1 and 5:1 when compared
with the isotype control. In the absence of NK cells, minimal cyto-
toxicity was observed with 3F2-3M (Figure 3).
Because 3F2-3M binds to NK cells, which play significant roles in
mediating the ADCC activity of 3F2-3M, we wanted to determine
whether specific NK cell markers of activation were induced. In the
presence of EphA2-expressing tumor cell lines and healthy donor NK
cells, both 3F2-WT and 3F2-3M were capable of activating NK cells
as measured by the expression of the NK cell surface marker CD107a
(Figure 4). The increase in CD107a occurred in a dose-responsive
manner where 3F2-3M demonstrated approximate a two-fold and
eight-fold increase in CD107a expression when compared with
3F2-WT and isotype control, respectively (Figure 4). Detectable cell
surface CD107a expression was observed at a 10-fold lower concen-
tration of 3F2-3M antibody compared with 3F2-WT. In addition,
EphA2 expression on the tumor cells was required for NK cell acti-
vation (data not shown).
Given that the FcγRIIIA allotype can impact the ability of other
monoclonal antibodies, such as Rituxan, to elicit ADCC activity and
effect patient outcomes [26,27], we assessed ADCC activity elicited by
3F2-3Musing effector cells isolated from healthy donors expressing the
FcγRIIIA 158 allotypes of VF, FF, or VV and A549 cells as the target
tumor cell line (Figure 5). With the FcγRIIIa 158 V/F and F/F allo-
types the 3F2-WT antibody demonstrated very low (10% or less)
ADCC activity, whereas the 3F2-3M molecule demonstrated 20%
ADCC activity; this translated into a two-fold to four-fold improve-
ment over 3F2-WT in tumor cell killing at the highest concentration
examined (Figure 5, A, C , andD). With the FcγRIIIa 158 V/Vallotype,
both the 3F2-WT and 3F2-3M molecules were capable of eliciting
ADCC activity Figure 5B. In addition, there was a shift in the dose-
response curve to the left, which reflected that a lower dose of 3F2-3M
antibody was required to initiate the ADCC-mediated cytotoxic re-
sponse (Figure 5). Overall, these data demonstrate that 3F2-3M is
Figure 4. CD107a expression is increased on NK cells in the pres-
ence of EphA2 antibodies. The expression of the activation marker
CD107a was evaluated on the surface of healthy donor NK cells by
flow cytometry. Isolated NK or non–NK cells were incubated in the
presence of tumor cells expressing or lacking EphA2, EphA2 anti-
bodies, or isotype control antibodies. When EphA2-expressing
tumor cells are present, a dose-responsive increase in CD107a
protein occurs with both the 3F2-WT (open squares) and 3F2-3M
(solid squares) antibodies, where 3F2-3M> 3F2-WT. At high concen-
trations of antibody, CD107a expression increases in a nonspecific
fashion as observed with the isotype control antibody (open circles)
and with EphA2-negative cell lines (data not shown). Error bars, SEM.
3F2-3Mwas statistically different from both 3F2-WT and isotype con-
trol antibody at all concentrations greater than 0.010 μg/ml (P< .001).
Figure 3. NK cells are required for ADCC activity in vitro. The ADCC
activity of 3F2-3Mwas evaluated in purified NK and non–NKcells iso-
lated from healthy donors as described in Materials and Methods.
Potent and reproducible ADCC activity against MDA-MB-231 cells
(A) and A549 NSCLC cells (B) in the presence of human purified NK
cells but not purified NK-depleted PBMCs. Error bars, SEM. Antibody
concentrations tested were 5 ng/ml (diamonds), 50 ng/ml (hatched
lines), and 500 ng/ml (solid bars) at an effector-to-target ratio of 10:1
for the MDA-MB-231 study and 5:1 for the A549 study. Data are rep-
resentative of two independent experiments.
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capable of eliciting in vitroADCC-mediated cytotoxicity regardless of the
FcγRIIIa allotype present in the donor PBMCs.
3F2-3M Is Efficacious In Vivo
To determine whether the in vitro activity of 3F2-3M translates into
in vivo antitumor activity and to understand the role that NK cells may
play in its activity, several tumor xenograft models using nude, SCID,
and SCID/NOD mice were evaluated. To verify that 3F2-3M retained
efficacy comparable to the parental antibody B233, an orthotopic
MDA-MB-231 breast cancer model was evaluated in female nude mice
(Figure 6A).When 3F2-3Mwas administered twice per week in a breast
tumor xenograft orthotopic model using nude mice, a significant inhi-
bition of tumor growth was demonstrated compared with the animals
treated with isotype control antibody or PBS (Figure 6A; P < .009).
To determine the potential contribution of the ADCC mechanism
of action, we compared the activity of 3F2-3M and 3F2-WT in
SCID mice, which possess NK cells, with that in SCID/NOD mice,
which lack NK cells. As shown in Figure 6B, a significant suppression
of tumor growth was observed in the 3F2-3M–treated SCID mice
compared with the 3F2-3M–treated SCID/NOD mice or the PBS
or isotype control groups in either mouse strain (P < .001). The
3F2-WT–treated SCID mice also showed significant tumor suppres-
sion compared with the 3F2-WT–treated SCID/NOD mice (P <
.031). In addition, there was a significant difference between the
3F2-3M– and 3F2-WT–treated SCID mice (P < .001), which sug-
gests that the in vivo antitumor activity of 3F2-3M is dependent, in
part, on the presence of NK cells.
Discussion
In this study, we report the development of an EphA2 agonist anti-
body, which, through three mutations in the Fc region, has enhanced
ADCC activity and antitumor efficacy. We demonstrate that 3F2-3M
retains agonist activity, is active both in vitro and in vivo, and, in part,
requiresNK cells for tumor cell killing. Thus, 3F2-3Mhas two potential
mechanisms for targeting EphA2 on cancer cells and hence provides a
new therapeutic strategy for the treatment of EphA2-expressing cancers.
The results from this study create an interesting paradigm for the role
of antibodies in targeting EphA2 as a cancer therapeutic; an agonist
EphA2 monoclonal antibody that is capable of decreasing cell surface
expression of EphA2 but can also drive ADCC, which requires EphA2
on the cell surface. One possibility is that the agonist EphA2 antibody,
by mimicking the action of the ligand, pushes the tumor cells toward
a more “normal cell” phenotype by initiating a proposed normal cell
signaling cascade where by there is activation, downstream signaling,
EphA2 degradation, and de novo synthesis of EphA2 (Figures W3
and W4). This is supported in part by studies demonstrating that small
Figure 5. Impact of FcγRIIIA polymorphisms on ADCC activity. Natural killer cells isolated from healthy human donors expressing
the FcγRIIIA 158 V/F, F/F, or V/V polymorphisms were evaluated in the LDH release cytotoxicity assay using A549 NSCLC cells as targets
(E/T = 2:1). 3F2-3M (solid triangles) elicited robust cytotoxicity independent of the FcγRIIIa allotype. The 3F2-WT (solid squares) antibody
demonstrated higher cytotoxicity using the V/V allotype compared with either the V/F or the F/F allotype: (A) V/F, (B) V/V, (C) F/F. Isotype
control antibody is represented as open squares. Net cell lysis across independent experiments is represented in (D) where *P < .0022,
comparing 3M to WT for each allotype.
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interfering RNA–mediated down-regulation of EphA2 expression, as
well as other approaches, results in decreased tumor growth in vivo
[16–20]. However, a decrease in EphA2 expression or the initiation
of downstream signaling alone may not be sufficient as demonstrated
in the study by Kiewlich et al. [30], where their EphA2 agonist anti-
bodies, although able to downregulate EphA2 protein, failed to demon-
strate antitumor activity. By having the additional potency of an ADCC
effector–enhanced antibody, direct tumor cell targeting by activation
of NK cells may overcome the resistance to normal EphA2 signaling
cascades and regulation.
Antibody-dependent cell-mediated cytotoxicity is a predominant
mechanism of action for a number of therapeutic monoclonal anti-
bodies, including Rituxan and Herceptin [24]. Furthermore, clinical
data suggest that the FcγRIIIa polymorphism status of cancer patients
plays a key role in the clinical outcome of patients receiving Rituxan
or Herceptin [26–28]. In the case of non–Hodgkin lymphoma, the
FcγRIIIa 158 V/V genotype was associated with both clinical and
molecular positive responses to Rituxan [27]. In further studies on
indolent lymphoma [31] and extended to Waldenstrom macroglobuli-
nemia in autoimmune disease, there is a correlation between FcγRIIIa
158 V/V polymorphism status and patient responses to Rituxan [32].
Thus, antibody engineering approaches to enhance ADCC have
resulted in improved in vitro ADCC activity mediated by NK cells
expressing the various FcγRIIIa polymorphisms that has translated into
increased efficacy [33,34]. It has been demonstrated that with the same
three mutations in the Fc region of alemtuzumab and trastuzumab, a
2- to 3-log increase in affinity to both FcγRIIIa variants, 158V and
158F, occurred, which translated into a similar 2- to 3-log improvement
in potency in vitro across the various 158 V/V, V/F, and F/F allotypes
[34]. An alternative approach using a low-fucose version of Rituxan,
KM3065, also demonstrated increased affinities and in vitro ADCC
activity to the FcγRIIIa allotypes [35]. In our current study, the three
modifications to the Fc portion of our 3F2-3M EphA2 agonist mono-
clonal antibody increased the affinity to both the FcγRIIIa 158V and
158F allotypes, and this resulted in increased in vitro ADCC activity
using effector cells from donors expressing the V/V, V/F, and F/F allo-
types (Figures 1 and 5). Given the prevalence of FcγRIIIA 158 F allele
(40% V/F and 40% F/F) in the general population, our results suggest
that 3F2-3M has the potential to impact a much larger and hetero-
geneous cancer patient population and thus may have an advantage
over current non–effector-enhanced monoclonal antibody therapies.
The activation of NK cells can also be a surrogate marker of ADCC
activity, and this can be measured by an increase in cell surface expres-
sion of CD54, CD69, or CD107a. Several studies have evaluated NK
cell activation with ADCC-enhanced antibodies as well as the effects
of FcγRIIIA polymorphisms on the activation potential [35–37]. A re-
cent study by Fischer et al. using Rituxan and alemtuzumab in chronic
lymphocytic leukemia patients demonstrated that increased CD107a
expression on peripheral blood NK cells correlated with ADCC activity
and suggested a possible means to measure ADCC activity in the clini-
cal setting. Our in vitro data support the use of CD107a as a marker
for NK cell activation and ADCC activity where, at very low concentra-
tions (10−2 μg/ml), 3F2-3M demonstrated robust increases in NK cell
surface CD107a expression, which was dependent on the presence of
EphA2-expressing tumor cells lines (Figure 4). These combined results
provide a potential avenue to monitor the ADCC activity of mono-
clonal antibodies, which could act as a clinical pharmacodynamic
marker, facilitate dose and scheduling optimization, and minimize clini-
cal trial durations. Furthermore, use of CD107a in conjunction with
other NK cell activation markers, such as CD54 and CD69, may fur-
ther increase the specificity of monitoring ADCC activity and have
broad applicability to monoclonal antibody therapies for oncology.
In summary, our preclinical evaluations of the EphA2 agonist anti-
body 3F2-3M demonstrate robust ADCC activity and the potential to
overcome the FcγRIIIa polymorphism obstacles that have challenged
other therapeutic monoclonal antibodies. Thus, by combining the
Figure 6. 3F2-3M is efficacious in vivo. The in vivoefficacy of 3F2-WT
and 3F2-3M was evaluated in nude, SCID, and SCID/NOD mice.
3F2-3M demonstrated significant suppression of MDA-MB-231
tumor growthwhen administered twice per week in the nudemouse
mammary fat pad model (A) (P < .009): isotype control (solid trian-
gles), 3F2-3M (solid upside-down triangles), taxol positive control
(solid diamonds). In addition, the role ofNK cells on antitumor activity
was evaluated using SCID and SCID/NODmousemodels (B). Signifi-
cant suppression of tumor growth was observed with the 3F2-3M–
treated SCID mice compared with the 3F2-3M–treated SCID/NOD
mice and control-treated animals (P < .001). The 3F2-WT–treated
SCID mice also showed significant tumor suppression compared
with the 3F2-WT–treated SCID/NOD mice (P < .031). In addition,
there was a significant difference between the 3F2-3M– and
3F2-WT–treated SCIDmice (P< .001): isotype control (open circles),
3F2-WT (open triangles), and 3F2-3M (open squares). In SCID/NOD
animals: isotype control (solid circles), 3F2-WT (solid triangles), and
3F2-3M (solid squares). Data are representative of two independent
experiments. Error bars, SEM.
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activation of EphA2 receptor–mediated signaling events with enhanced
ADCC activity in 3F2-3M, we have generated a novel and potent
therapeutic approach for the potential treatment of cancer patients with
tumors that overexpress EphA2.
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Figure W1. 3F2-WT and 3F2-3M activate EphA2 in vitro. EphA2
agonist activity of 3F2-WT, 3F2-3M, and control antibodies was
determined by evaluating EphA2 phosphorylation in HeyA8 human
ovarian carcinoma cells at 10 μg/ml as described in Materials
and Methods.
Figure W2. 3F2-3M activates EphA2 in vitro. EphA2 agonist activity
of 3F2-3M was determined by evaluating EphA2 phosphorylation
in HeyA8 ovarian carcinoma cells at concentrations from 0.1 to
50 μg/ml as described in Materials and Methods. Control antibodies
were evaluated at 10 μg/ml.
Figure W3. 3F2-3M induces degradation of EphA2 in vitro. Degra-
dation of EphA2 was determined by treating MDA-MB-231 cells
with 10 μg/ml of 3F2-3M antibody for 24 to 72 hours. Lysates were
collected as described for EphA2 activation assays. Equal proteins
were resolved by SDS-PAGE, transferred to polyvinylidene fluoride
membrane, and immunoblotted with anti-EphA2 (Invitrogen) or anti–
β-actin antibodies (Sigma).
Table W1. Summary of 3F2-3M ADCC Activity in a Panel of Human Cancer Cell Lines.
Cell Line Tumor Type EphA2 Expression through FACS Fold Log Change over Secondary Percent Cytotoxicity (E/T, 50:1; 500 ng/ml)
A549 NSCLC 3 ∼65%
T231 Breast 3 ∼36%
MDA-MB-231 Breast 2 ∼20% (E/T = 30:1
A498 Renal cell carcinoma 1 ∼45%
HeyA8 Ovarian 3 ∼40%
SKOV3 Ovarian 2 ∼20%
M21 Melanoma 0 <10%
SKMel28 Melanoma 0 <10%
Figure W4. 3F2-3M treatment induces degradation of cell surface EphA2 in vivo. MDA-MB-231 breast carcinoma
cells (2 × 106) were implanted proximal to the mammary fat pad of female nude mice. Once tumors reached
approximately 150 mm3, mice were given a single intraperitoneal injection of either 3F2-3M or isotype control
at 10 mg/kg. Tumors were then harvested at 24, 48, 72, 168, and 336 hours after 3F2-3M administration. Tumors
were dissociated with collagenase into a single-cell suspension, stained, and analyzed by FACS using an EphA2
antibody that does not compete with 3F2-3M. Two-way analysis of variance revealed that at 24, 48, 72, 168, and
336 hours, EphA2 levels at the cells surface of tumor cells treated with 3F2-3M are statistically lower than those
treated with the isotype control antibody: *P < .05, **P < .001 to .01, ***P < .001.
